Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753676 | 0.83 | ALDH1A1 (0.43) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL195987 | 0.81 | PARP1 (0.48) | MAPTMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL6152607 | 0.78 | MAPT (0.39) | CYP2A6NPC1RAB9AMAPTMEN1 | |
| SCHEMBL1636144 | 0.78 | ATM (0.42) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL1100872 | 0.78 | CA1 (0.48) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL745428 | 0.78 | ALDH1A1 (0.41) | NPC1ALDH1A1TDP1SMN1; SMN2HPGD | |
| SCHEMBL2635549 | 0.78 | HDAC6 (0.52) | — | |
| SCHEMBL743658 | 0.78 | HDAC8 (0.47) | SMN1; SMN2HPGD | |
| SCHEMBL561510 | 0.77 | NPC1 (0.38) | CYP2A6NPC1RAB9AMAPTMEN1 | |
| SCHEMBL6975368 | 0.77 | TDP1 (0.41) | CYP2A6NPC1RAB9AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107235995-A | A kind of chiral two silane compound and its synthetic method and application | 浙江大学 | 2017-10-10 | — | — | CN | claimed |
| US-7132420-B2 | Aspartic protease inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-11-07 | — | — | US | claimed |
| US-20050090546-A1 | Aspartic protease inhibitors | GOVERNMENT OF THE USA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-04-28 | — | — | US | claimed |
| US-6613764-B1 | Compounds such as N,N-dibenzylphenylalanine benzyl ester, used as enzyme inhibitors; prophylaxis of lymphadenopathy associated virus, cancer and malaria | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-09-02 | — | — | US | claimed |
| EP-1140846-A1 | ASPARTIC PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040558-A1 | ASPARTIC PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-07-13 | — | — | WO | claimed |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2022-11-17 | — | — | US | disclosed |
| US-20200231563-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2020-07-23 | — | — | US | disclosed |
| EP-3672950-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | Pragma Therapeutics (FR) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019063596-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2019-04-04 | — | — | WO | disclosed |
| EP-3459939-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | Pragma Therapeutics (FR) | 2019-03-27 | — | — | EP | disclosed |
| CN-107235995-A | A kind of chiral two silane compound and its synthetic method and application | 浙江大学 | 2017-10-10 | — | — | CN | disclosed |
| CN-101027290-B | 2, 3-phthalazinone derivatives as AURORA-a kinase inhibitors | HOFFMANN LA ROCHE | 2010-05-12 | — | — | CN | disclosed |
| EP-0678505-B1 | Oximethers and fungicides containing them | BASF AG (DE) | 1997-06-04 | — | — | EP | disclosed |
| EP-0498188-B1 | Oximethers and fungicides containing them | BASF AG (DE) | 1996-03-27 | — | — | EP | disclosed |
| EP-0679636-A1 | Oximethers and fungicides containing them | BASF Aktiengesellschaft (DE) | 1995-11-02 | — | — | EP | disclosed |
| EP-0678505-A1 | Oximethers and fungicides containing them | BASF AKTIENGESELLSCHAFT (DE) | 1995-10-25 | — | — | EP | disclosed |
| US-5446067-A | For treatment of crops, seeds, soils | BASF AKTIENGESELLSCHAFT (DE) | 1995-08-29 | — | — | US | disclosed |
| EP-0498188-A2 | Oximethers and fungicides containing them | BASF Aktiengesellschaft (DE) | 1992-08-12 | — | — | EP | disclosed |
| US-4366236-A | HYDROQUINONE DERIVATIVE LAYER AND A WATER INSOLUBLE POLYMER | FUJI PHOTO FILM CO., LTD. (JP) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231563-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM3 | CYP2A6 3700/4885NPC1 1478/4885RAB9A 1171/4885 |
| US-20220363664-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | CYP2A6 3348/4885NPC1 958/4885RAB9A 1312/4885 |
| US-20050090546-A1 | Aspartic protease inhibitors | DPP7, SENP7, DNPEP | CYP2A6 2361/4885NPC1 1395/4885RAB9A 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.